[American Depository Receipt 16112R101 September 30, 2014 [ ] Rule 13d-1(b) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. CUSIP No.: 16112R101]
[American Depository Receipt 16112R101 September 30, 2014 [ ] Rule 13d-1(b) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. CUSIP No.: 16112R101]
[Montage Receives Notice of Delisting from NASDAQ SHANGHAI, China, October 2, 2014 NASDAQs delisting determination will not immediately result in the delisting of the Companys ordinary shares. The Company intends to commence such an appeal by the required deadline, which is within seven days of the date of the notice. NASDAQ will generally suspend the delisting for a period of] [Item 3.01 Notice of Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing NASDAQs delisting determination will not immediately result in the delisting of the Companys ordinary shares. The Company intends to commence such an appeal by the required deadline, which is within seven days of the date of the notice. NASDAQ will generally suspend the delisting]
[Montage Receives Notice of Delisting from NASDAQ SHANGHAI, China, October 2, 2014 NASDAQs delisting determination will not immediately result in the delisting of the Companys ordinary shares. The Company intends to commence such an appeal by the required deadline, which is within seven days of the date of the notice. NASDAQ will generally suspend the delisting for a period of] [Item 3.01 Notice of Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing NASDAQs delisting determination will not immediately result in the delisting of the Companys ordinary shares. The Company intends to commence such an appeal by the required deadline, which is within seven days of the date of the notice. NASDAQ will generally suspend the delisting]
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 6 11 2 WuXi PharmaTech (Cayman) Inc.]
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 6 11 2 WuXi PharmaTech (Cayman) Inc.]
[Form 6-K TABLE OF CONTENTS Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
[Form 6-K TABLE OF CONTENTS Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
